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  EVIDENCE-BASED ANSWER 
If statins (HMG-CoA reductase inhibitors) cause myopathy, the risk is very low (strength of recommendation 
[SOR]: A). There is no direct evidence to answer this question. A pooled analysis of randomized controlled 
trials found similar myopathy rates in patients taking statins and placebo. However, a large cohort study 
revealed a very small but statistically significant increased risk of myopathy in patients taking statins (number 
needed to harm=10,000/year). 
Case reports suggest a myopathy risk for all statins, including fatal rhabdomyolysis. Risk of myopathy may 
increase with higher statin doses, certain comorbid states (eg, hypothyroidism, renal insufficiency [especially 
with diabetes], recent trauma, perioperative periods, advanced age, small body frame) and concurrent 
medications, including fibrates, cyclosporine, azole antifungals, and macrolide antibiotics (SOR: B). No studies 
have directly compared myopathy rates among statins, and there is no good evidence to suggest any 
differences. No controlled study has directly examined statin rechallenge in patients with previous myopathy; 
however, case reports and expert opinion support this practice (SOR: B). 
  EVIDENCE SUMMARY 
There is little evidence that statins cause myopathy. Synthesis is difficult because definitions of myopathy types 
differ among investigators. Proposed clinical syndrome definitions are myalgia (muscle weakness or ache with 
normal creatine kinase), myositis (symptoms with increased creatine kinase), and rhabdomyolysis (symptoms, 
markedly elevated creatine kinase, and renal insufficiency) as subsets of the more general term myopathy.1 
The Table summarizes myopathy data from 30 statin trials analyzed in a recent systematic review, showing 
similar myopathy rates in statin and placebo patients.2 There may be a lower myopathy rate in these trials than 
in routine clinical practice because of stricter exclusion criteria and more intense monitoring. 
A large well-done British epidemiologic cohort study (n=96,193) found an increased rate of myopathy (broadly 
defined, not requiring creatine kinase elevation) among patients taking statins, with an absolute rate difference 
of 1 per 10,000 person-years.3 A small study of 21 patients on statins with muscle symptoms but normal 
creatine kinases described 4 patients who were able to distinguish statins from placebo, with objective 
reversible weakness and abnormal muscle biopsies.4 Postmarket voluntary clinician reports point to statin 
myopathy in this and other countries;5-7 these include 3339 rhabdomyolysis FDA reports (1990 to March 
2002).2 
Though some assert differential myopathy rates among statins based on cell research, case reports, or 
differences in metabolic clearance, no studies directly compare clinical myopathy rates among statins. There is 
no good evidence of a differential myopathy risk among statins currently available in the US.1-2 Cerivastatin, 
however, was withdrawn from the US market because of a fatal rhabdomyolysis rate 16 to 80 times higher than 
other statins based on FDA reports using a denominator of prescription volume (3.16 fatal cases/million 
prescriptions vs 0.15 for the statin class as a whole).6 
It is unknown whether previous myopathy, however defined, increases the risk of future myopathy with statin 
rechallenge. A tabular analysis of 74 published case reports of statin-associated rhabdomyolysis from a 
MEDLINE search covering 1985 to 2000 reported that in most cases the statin was safely restarted after 
stopping presumed interactive drugs (exact numbers not reported).8 In the AFCAPS/TexCAPS trial, 20 of 21 
statin patients (out of a study population of 3304) who had elevated creatine kinase (>10 times the upper limits 
of normal) recovered with continued lovastatin treatment, while the other patient resumed treatment after a 
brief interruption without further elevations.9 The EXCEL trial (n=8245) of various lovastatin dosages included 
routine creatine kinase tests every 6 weeks for 48 weeks. Five lovastatin patients had muscle symptoms with 
creatine kinases >10 times the upper limits of normal, and in the 2 who continued treatment, symptoms and 
creatine kinase became normal.10 Of note, creatine kinase elevation of any kind at least once during 48 weeks 
occurred in 28.9% of placebo patients, arguing against routine creatine kinase screening in statin patients. 
Case studies suggest an increased myopathy risk when statins are given with various medications, including 
fibrates, cyclosporine, azole antifungals, warfarin, nefazodone, and macrolide antibiotics.4,6,8 Pravastatin and 
fluvastatin, which are not metabolized by the P450 CYP3A4 pathway, may be safer to use because of fewer 
drug interactions.2,8 Likewise, certain comorbid states such as hypothyroidism, renal insufficiency (especially in 
patients with diabetes), recent trauma, and perioperative periods, as well as advanced age, small body frame, 
and multiple medications may increase statin myopathy risk.1,2,7,8 
 
TABLE 
Pooled myopathy data from 30 randomized controlled statin trials 
  Trials 
Total 
patients 
Statin 
patients 
Placebo 
patients 
Myalgia 5 33,929 
0.3–
32.9% 
0–33.3% 
Creatine kinase 
elevation 
9 33,921 0–0.64% 0–0.58% 
Myositis* 18 58,237 0.17% 0.15% 
Rhabdomyolysis 20 70,126 0.020% 0.014% 
*Creatine kinase >10 times upper limit of normal 
Adapted and calculated from Thompson PD, et al. JAMA 2003; 289:1681–1690.2 
  RECOMMENDATIONS FROM OTHERS 
A 2002 Clinical Advisory, jointly issued by the American College of Cardiology, the American Heart 
Association, and the National Heart, Lung and Blood Institute, asserted that statins carry a small but definite 
myopathy risk.1 It recommended against routine creatine kinase tests, reserving them for patients who develop 
muscle symptoms. It also recommended stopping statins when muscle symptoms with creatine kinase 
elevations >10 times the upper limits of normal occur, with consideration of restarting statins later at a lower 
dose if symptoms and elevated creatine kinase resolve. Careful monitoring of patients at higher risk of statin 
myopathy is also recommended. 
CLINICAL COMMENTARY 
Benefits of statins outweigh the risks 
 
Joseph  Saseen,  PharmD, BCPS 
University of Colorado Health Sciences Center, Denver 
Contrary to popular belief, statin-associated myopathy is a rare adverse event. Drug-drug 
interactions and comorbid diseases (especially chronic kidney disease) increase 
myopathy risk. Given the overwhelming evidence demonstrating reduced morbidity and 
mortality with statins, benefits outweigh risks in patients with elevated low-density 
lipoprotein cholesterol. Data supporting myopathy management strategies are limited, but 
support stopping statin therapy in patients with myopathy (muscle aches/pain with 
elevated creatine kinase), and restarting, possibly with a different statin, after symptoms 
resolve. Myopathy should not be confused with myalgia (muscle aches/pain with normal 
creatine kinase). Myalgia requires interrupting treatment only for patients with persistent 
muscle aches/pain while on statin therapy. 
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